EUVIMED · CrossrefZeitschrift
Annals of the Rheumatic Diseases
ISSN 0003-4967 · Elsevier BV
Neueste Artikel
Broad screening of inflammation-associated proteins identifies serum CCL19 as a novel biomarker of disease activity in IgG4-related disease
Corrigendum to Osteoarthritis risk associated with romosozumab compared with teriparatide in individuals with osteoporosis: A target trial emulation study Ann Rheum Dis 2025;84(11):1938-1947
Correspondence on ‘Development and validation of a model to predict the disease activity score: towards a remote treat-to-target approach for rheumatoid arthritis’ by Looijen et al
Correspondence on ‘Spacing of a TNF inhibitor or dose reduction of methotrexate vs continued treatment in patients with rheumatoid arthritis in remission or low disease activity (SORAIRO trial)’ by Imai et al
Response to correspondence on ‘Development and validation of a model to predict the disease activity score: towards a remote treat-to-target approach for rheumatoid arthritis’ by Zhang et al
Response to correspondence on ‘Spacing of a TNF inhibitor or dose reduction of methotrexate vs continued treatment in patients with rheumatoid arthritis in remission or low disease activity (SORAIRO trial)’
Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN) consensus statement regarding labels and definitions for disease elements in calcium pyrophosphate crystal deposition (CPPD)
Autologous stem cell transplantation (ASCT) for Refractory juvenile-onset systemic sclerosis (JSSc)
Teclistamab induces rapid clinical response and deep tissue depletion in refractory systemic sclerosis—a case series
Longitudinal profiling reveals immune dynamics and distinct plasma cell signatures during B-cell depletion in IgG4-related disease
Instrument selection for the assessment of peripheral arthritis in axial and peripheral spondyloarthritis: an ASAS project
Genetic biomarkers of clinical manifestations in giant cell arteritis define distinct patient subgroups
Remission of refractory lupus nephritis is temporally associated with antitumour therapy, including durvalumab for endometrial carcinoma
Ultrasound-defined presynovitis is associated with progression to clinical arthritis in ACPA-positive individuals at risk of rheumatoid arthritis: longitudinal insights from the Karolinska Risk-RA cohort
A novel STAT4 gain-of-function variant defines a monogenic form of juvenile-onset systemic lupus erythematosus
Rheumatoid arthritis susceptibility genes show pathotype-specific expression in synovial tissue of patients with early treatment-naïve RA
Correspondence on ‘Composite outcome measures that successfully differentiate active treatments from placebo in psoriatic arthritis trials’ by Annfeldt et al
High-throughput plasma proteomics reveals circulating biomarkers of interstitial lung disease and progressive pulmonary fibrosis in systemic sclerosis
Correspondence on ‘Teclistamab induces rapid clinical response and deep tissue depletion in refractory systemic sclerosis—a case series’ by Siegert et al
A global OMERACT ultrasound joint damage scoring system (GLODS) in rheumatoid arthritis
Response to correspondence on ‘Composite outcome measures that successfully differentiate active treatments from placebo in psoriatic arthritis trials’ by Annfeldt et al
Corrigendum to EULAR/ACR risk stratification criteria for development of rheumatoid arthritis in the risk stage of arthralgia Ann Rheum Dis. 2025 Sep;84(9):1445-1457. doi: 10.1016/j.ard.2025.01.021. Epub 2025 May 8
Improvement in neuropsychological function with memantine treatment among patients with systemic lupus erythematosus: a phase 2 randomised placebo-controlled clinical trial
Impact of disease activity on bone density, microarchitecture, and biomechanical properties in rheumatoid and psoriatic arthritis over 7 years
Response to a Correspondence on ‘Teclistamab induces rapid clinical response and deep tissue depletion in refractory systemic sclerosis – a case series’
Use of parenteral compared with oral glucocorticoids in early rheumatoid arthritis for chance of being off steroids and escalation of therapy at 1 year
Difficult-to-manage and treatment-refractory psoriatic arthritis in patients treated with biological and targeted synthetic DMARDs: prevalence and characteristics in 5 Nordic registries
Performance of a triage approach for identification of patients with inflammatory rheumatic and musculoskeletal diseases among rheumatology referrals
Conceptual framework for the definition of disease modification in systemic sclerosis and potential implications for drug development and clinical study design
Estimating 2-year risk of first relapse in ANCA-associated vasculitis: derivation of a risk-prediction model based on participants in the PEXIVAS trial
Jahrgänge
2026 · 3232025 · 3.3412024 · 3.6542023 · 3.4702022 · 4.0112021 · 3.2232020 · 4.1322019 · 4.8502018 · 4.8452017 · 4.7142016 · 4.2322015 · 4.4122014 · 4.1952013 · 3.8472012 · 4.0722011 · 7122010 · 6632009 · 4102008 · 4272007 · 4042006 · 4312005 · 5472004 · 4392003 · 4072002 · 4032001 · 1.6412000 · 2881999 · 2161998 · 2181997 · 2071996 · 2681995 · 2891994 · 2731993 · 3001992 · 3911991 · 3191990 · 3811989 · 2891988 · 2551987 · 259
EUVIMED